BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29468405)

  • 1. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma.
    Kusuhara S; Katsuyama A; Matsumiya W; Nakamura M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):809-814. PubMed ID: 29468405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma.
    Komizo T; Ono T; Yagi A; Miyata K; Aihara M
    Jpn J Ophthalmol; 2019 Jan; 63(1):40-45. PubMed ID: 30368633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy.
    Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2009-2015. PubMed ID: 28711991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Long-Term Ripasudil 0.4% Instillation for the Reduction of Intraocular Pressure in Japanese Open-Angle Glaucoma Patients.
    Maruyama Y; Ikeda Y; Mori K; Yoshii K; Ueno M; Sotozono C; Kinoshita S
    J Ocul Pharmacol Ther; 2020 May; 36(4):229-233. PubMed ID: 32175792
    [No Abstract]   [Full Text] [Related]  

  • 5. Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study.
    Futakuchi A; Morimoto T; Ikeda Y; Tanihara H; Inoue T;
    Sci Rep; 2020 Jun; 10(1):10308. PubMed ID: 32587304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy.
    Sato S; Hirooka K; Nitta E; Ukegawa K; Tsujikawa A
    Adv Ther; 2016 Sep; 33(9):1628-34. PubMed ID: 27438467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil.
    Inoue K; Ishida K; Tomita G
    Jpn J Ophthalmol; 2018 Jul; 62(4):508-516. PubMed ID: 29797109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Fukushima A; Suganami H; Araie M;
    Acta Ophthalmol; 2016 Feb; 94(1):e26-34. PubMed ID: 26338317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
    Acta Ophthalmol; 2015 Jun; 93(4):e254-60. PubMed ID: 25487877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure.
    Inoue K; Okayama R; Shiokawa M; Ishida K; Tomita G
    Int Ophthalmol; 2018 Feb; 38(1):93-98. PubMed ID: 28063100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy.
    Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
    J Glaucoma; 2017 Feb; 26(2):96-100. PubMed ID: 27661993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15.
    Sakata R; Fujishiro T; Saito H; Honjo M; Shirato S; Aihara M
    Adv Ther; 2021 Jul; 38(7):3760-3770. PubMed ID: 34028695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months.
    Tanihara H; Kakuda T; Sano T; Kanno T; Kurihara Y
    Adv Ther; 2022 Apr; 39(4):1659-1677. PubMed ID: 35150417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study.
    Tanihara H; Kakuda T; Sano T; Kanno T; Imada R; Shingaki W; Gunji R
    Adv Ther; 2019 Feb; 36(2):333-343. PubMed ID: 30610614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase in the OCT angiographic peripapillary vessel density by ROCK inhibitor ripasudil instillation: a comparison with brimonidine.
    Chihara E; Dimitrova G; Chihara T
    Graefes Arch Clin Exp Ophthalmol; 2018 Jul; 256(7):1257-1264. PubMed ID: 29520478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study.
    Tanihara H; Kakuda T; Sano T; Kanno T; Gunji R
    BMC Ophthalmol; 2020 Jul; 20(1):275. PubMed ID: 32646383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-Year Efficacy and Safety Assessment of Ripasudil, a Rho Kinase Inhibitor, in an Addition to or Replacing Existing Treatment Regimens: A Retrospective Study.
    Tsukahara S; Enomoto N; Ishida K; Anraku A; Tomita G
    J Ocul Pharmacol Ther; 2020 Sep; 36(7):512-521. PubMed ID: 32412867
    [No Abstract]   [Full Text] [Related]  

  • 18. Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4.
    Terao E; Nakakura S; Fujisawa Y; Fujio Y; Matsuya K; Kobayashi Y; Tabuchi H; Yoneda T; Fukushima A; Kiuchi Y
    Curr Eye Res; 2017 May; 42(5):738-742. PubMed ID: 27911106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial.
    Sakamoto E; Ishida W; Sumi T; Kishimoto T; Tada K; Fukuda K; Yoneda T; Kuroiwa H; Terao E; Fujisawa Y; Nakakura S; Jian K; Okumichi H; Kiuchi Y; Fukushima A
    Sci Rep; 2019 Mar; 9(1):3755. PubMed ID: 30842572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ripasudil hydrochloride hydrate (K-115), a Rho-kinase inhibitor, on ocular blood flow and ciliary artery smooth muscle contraction in rabbits.
    Ohta Y; Takaseki S; Yoshitomi T
    Jpn J Ophthalmol; 2017 Sep; 61(5):423-432. PubMed ID: 28653193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.